Testing a Pill Called JZP3507 for Grade 2 or 3 Meningioma That Came Back
Original title: A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage test in people, and the answers are not in yet.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a pill for people whose grade 2 or 3 meningioma came back after earlier treatment.
Who this trial is for. This trial is for people with a grade 2 or 3 meningioma who have already tried other treatment that did not work. They take JZP3507, also called ONC206, by mouth. The study is looking at how the tumor responds to the drug and how safe the drug is.
Where it stands. There are no results yet. The trial has not reported anything about how well the drug works. It is still measuring the drug's effect on the tumor and the side effects people have. Until that work is done, no one knows if this drug helps.
What this means, and what it doesn't
What it could mean: If you have a grade 2 or 3 meningioma that came back after treatment, this study may be worth asking your care team about. They know your case and can say whether it makes sense to look into. Being in a study is your choice.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that you will be helped. It is not a promise of a cure.
Source: ClinicalTrials.gov, July 30, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.